Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
Year: 2001
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Annals of Oncology
Authors: J.A. O’Shaughnessy, J. Blum, V. Moiseyenko, S.E. Jones, D. Miles, D. Bell, R. Rosso, L. Mauriac, B. Osterwalder, H.-U. Burger, S. Laws
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: capecitabine, CMF chemotherapy, advanced breast cancer, metastatic breast cancer, first-line chemotherapy, older women, oral chemotherapy, hand-foot syndrome, diarrhea, myelosuppression, overall response rate, survival, time to progression, outpatient therapy, toxicity management, cyclophosphamide, methotrexate, 5-fluorouracil
Open Access status: bronze
Funder: National Cancer Institute
OpenAlex ID: W2099658604
